ArticleAlzheimer's research & therapy2021
Salivary lactoferrin is associated with cortical amyloid-beta load, cortical integrity, and memory in aging.
Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Lactoferrin Levels in Cerebrospinal Fluid Exhibit Differential Associations with Alzheimer's Disease.Research square · 2026Article
- Lactoferrin levels in cerebrospinal fluid exhibits isoform-specific associations with Alzheimer's disease.medRxiv : the preprint server for health sciences · 2025Article
- Salivary lactoferrin levels in Down Syndrome: a case-control study.Brain, behavior, & immunity - health · 2025Article
- AuNP/Magnetic Bead-Enhanced Electrochemical Sensor Toward Dual Saliva Alzheimer's Biomarkers Detection.Sensors (Basel, Switzerland) · 2025Article
- Differences in Plasma Lactoferrin Concentrations Between Subjects with Normal Cognitive Function and Mild Cognitive Impairment: An Observational Study.Healthcare (Basel, Switzerland) · 2025Article
- Lactoferrin Attenuates Pro-Inflammatory Response and Promotes the Conversion into Neuronal Lineages in the Astrocytes.International journal of molecular sciences · 2025Article
- Association of salivary lactoferrin,Frontiers in immunology · 2025Article
- Reduced Salivary Lactoferrin Levels in Early-Onset Alzheimer's Disease.Aging and disease · 2024Article
- Article
- The role of microbiome-host interactions in the development of Alzheimer´s disease.Frontiers in cellular and infection microbiology · 2023Review
- Lactoferrin alleviates Western diet-induced cognitive impairment through the microbiome-gut-brain axis.Current research in food science · 2023Article
- Can Lactoferrin, a Natural Mammalian Milk Protein, Assist in the Battle against COVID-19?Nutrients · 2022Review
- Neuroprotective Role of Lactoferrin during Early Brain Development and Injury through Lifespan.Nutrients · 2022Review
- Salivary inflammatory biomarkers are predictive of mild cognitive impairment and Alzheimer's disease in a feasibility study.Frontiers in aging neuroscience · 2022Article
- Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer's Disease Patients.Frontiers in immunology · 2022Review
- Pilot: Salivary lactoferrin as a potential preclinical Alzheimer's disease biomarker.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAging is associated with declining protective immunity and persistent low-grade inflammatory responses, which significantly contribute to Alzheimer's disease (AD) pathogenesis. Detecting aging-related cerebral vulnerability associated with deterioration of the immune system requires from non-invasive biomarkers able to detect failures in the brain-immunity connection. Reduced levels of salivary lactoferrin (sLF), an iron-binding protein with immunomodulatory activity, have been related to AD diagnosis. However, it remains unknown whether decreased sLF is associated with increased cortical amyloid-beta (Aβ) load and/or with loss of cortical integrity in normal aging.
methodsSeventy-four cognitively normal older adults (51 females) participated in the study. We applied multiple linear regression analyses to assess (i) whether sLF is associated with cortical Aβ load measured by 18F-Florbetaben (FBB)-positron emission tomography (PET), (ii) whether sLF-related variations in cortical thickness and cortical glucose metabolism depend on global Aβ burden, and (iii) whether such sLF-related cortical abnormalities moderate the relationship between sLF and cognition.
resultssLF was negatively associated with Aβ load in parieto-temporal regions. Moreover, sLF was related to thickening of the middle temporal cortex, increased FDG uptake in the posterior cingulate cortex, and poorer memory. These associations were stronger in individuals showing the highest Aβ burden.
conclusionssLF levels are sensitive to variations in cortical Aβ load, structural and metabolic cortical abnormalities, and subclinical memory impairment in asymptomatic older adults. These findings provide support for the use of sLF as a non-invasive biomarker of cerebral vulnerability in the general aging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.